Acute Coronary Tree Thrombosis After Vaccination for COVID-19

The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review

“…The authors of this report wondered whether this early cytokine/chemokine response with increased CXCL10, IL-15 andIFN-g could be used to monitor effective vaccinations and/or as a guide to optimize the efficacy of the mRNA vaccination [111]. Extremely rare cases of acute myocardial infarction and Kounis syndrome have been reported in association with COVID-19 disease and the COVID-19 vaccination including BNT162b2 (Pfizer-BioNTech) [112], the Covishield vaccine [113,114], Sinovac (Coronovac) [115], Moderna [112,113,116] and AstraZeneca [117]. Whether these rare associations are the result of CXCL10 and other chemokines needs to be elucidated.…”

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?

“…Four different vaccines against COVID-19 have been authorized in the European Union (EU), following evaluation by the European Medicines Agency (EMA) so far, including two vaccines (Pfizer-BioNTech and AstraZeneca) that have been already used in millions of adults-and one of them (Pfizer-BioNTech) being recently approved even for children aged ≥ 12 years [1]. Beyond casual mild to moderate postvaccination side effects that normally disappear within a few hours/days, some other rare adverse effects such as cerebral venous sinus thrombosis, acute ST-segment elevation myocardial infarction (STEMI) with large thrombus in coronary arteries [2] as well as (autoimmune) myocarditis [3] have also been reported recently. We would like to present the findings of three different patients that presented to our hospital until mid of June 2021 and showed unusual serious adverse cardiovascular events of infarct-like myocarditis (in the absence of CAD), possibly linked to preceding COVID-19 vaccination.…”

Cardiovascular and haematological events post COVID‐19 vaccination: A systematic review

“…Tables [Link] , [Link] , [Link] , [Link] , [Link] summarize the types of studies and demographic data of the included patients who suffered from CV and haematological events following receiving Pfizer, Moderna, AstraZeneca, J&J and CoronaVac, respectively. 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ...…”